Meta-analysis of Six Excimer Laser Platforms for Safety and Efficacy in Myopic Laser-assisted in situ Keratomileusis
| Autor: | Christopher L Blanton |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Refractive error
medicine.medical_specialty Visual acuity genetic structures Excimer laser business.industry medicine.medical_treatment LASIK Keratomileusis medicine.disease Laser eye diseases law.invention law Meta-analysis Ophthalmology medicine Optometry sense organs medicine.symptom business Dioptre |
| Zdroj: | US Ophthalmic Review. 8:23 |
| ISSN: | 1756-1752 |
| DOI: | 10.17925/usor.2015.8.1.23 |
| Popis: | Purpose:To compare excimer laser platform outcomes for myopic laser-assistedin situkeratomileusis (LASIK).Methods:A peer-reviewed literature search was conducted using the terms “myopia,” “LASIK,” and “outcomes.” Articles were selected based on inclusion/exclusion criteria. Data regarding Snellen visual acuity, refractive error ± 0.5 and 1.0 diopter (D) and loss of best-corrected acuity were extracted. US Food and Drug Administration (FDA) approval studies were used to fill in any data gaps. Statistical analysis was performed.Results:The Abbott laser outperformed the other five in multiple measures of visual acuity results at 1 and 3 months. The Nidek laser outperformed the other five lasers at the 20/16 level at 6 months. The Carl Zeiss/Meditec laser outperformed the other five at 6 months in terms of refractive outcome ± 0.5 D. The Abbott and Alcon lasers outperformed the other four lasers in the safety category (least amount of >2 line loss of best-corrected visual acuity [BCVA]) at the 1 month visit. There were no significant differences between the platforms, in the safety category, at all other time intervals.Conclusion:At all times, all lasers fell within the FDA guidelines for safety regarding loss of bestcorrected acuity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|